key: cord-0806660-ucctwafv
authors: Ding, Yan; Zhou, Zining; Li, Xingyu; Zhao, Chen; Jin, Xiaoxiao; Liu, Xiaotao; Wu, Yandan; Mei, Xueyin; Li, Jian; Qiu, Jie; Shen, Chuanlai
title: Screening and Identification of HBV Epitopes Restricted by Multiple Prevalent HLA-A Allotypes
date: 2022-04-07
journal: Front Immunol
DOI: 10.3389/fimmu.2022.847105
sha: 8221c4fbf70b68259081b99279ad96e0093c8e12
doc_id: 806660
cord_uid: ucctwafv

Although host T cell immune responses to hepatitis B virus (HBV) have been demonstrated to have important influences on the outcome of HBV infection, the development of T cell epitope-based vaccine and T cell therapy and the clinical evaluation of specific T cell function are currently hampered markedly by the lack of validated HBV T cell epitopes covering broad patients. This study aimed to screen T cell epitopes spanning overall HBsAg, HBeAg, HBx and HBpol proteins and presenting by thirteen prevalent human leukocyte antigen (HLA)-A allotypes which gather a total gene frequency of around 95% in China and Northeast Asia populations. 187 epitopes were in silico predicted. Of which, 62 epitopes were then functionally validated as real-world HBV T cell epitopes by ex vivo IFN-γ ELISPOT assay and in vitro co-cultures using peripheral blood mononuclear cells (PBMCs) from HBV infected patients. Furthermore, the HLA-A cross-restrictions of each epitope were identified by peptide competitive binding assay using transfected HMy2.CIR cell lines, and by HLA-A/peptide docking as well as molecular dynamic simulation. Finally, a peptide library containing 105 validated epitopes which cross-binding by 13 prevalent HLA-A allotypes were used in ELISPOT assay to enumerate HBV-specific T cells for 116 patients with HBV infection. The spot forming units (SFUs) was significantly correlated with serum HBsAg level as confirmed by multivariate linear regression analysis. This study functionally validated 62 T cell epitopes from HBV main proteins and elucidated their HLA-A restrictions and provided an alternative ELISPOT assay using validated epitope peptides rather than conventional overlapping peptides for the clinical evaluation of HBV-specific T cell responses.

Hepatitis B virus (HBV) infections are still prevalent across the world. The global patients with chronic infection have exceeded 257 million which results in about 880,000 deaths per year due to liver cirrhosis (LC) or hepatocellular carcinoma (HCC) (1) . In China, currently about 70 million people have been infected with HBV, around 20-30 million people have suffered from chronic infections which is the main pathogenic factor for 77% of liver cirrhosis and 84% of HCC (2) . Liver inflammation induced by HBV is mainly caused by the host immune responses. Numerous researches have confirmed that HBV-specific T cells not only substantially drive virus clearance (3, 4) and disease progression (5) (6) (7) , but also significantly influence antiviral efficacy (8, 9) and disease recurrence after therapy discontinuation (10) (11) (12) . The immune responses mediated by HBV antigen-specific CD8 + T cells are particularly critical for host antiviral protections since CD8 + cytotoxic T lymphocytes (CTL) are the vital cells to kill virus-infected cells. Human leukocyte antigen (HLA) class I molecules (such as HLA-A, B, and C) expressed by virus-infected liver cells present the HBV epitope peptides to specific CD8 + T cells, thus initiate the activation, proliferation and differentiation of CTLs. However, HLA class I molecules are highly polymorphic in the general population. That means HLA class I allotypes are distinctive from individual to individual, and each HLA allotype presents distinctive epitope peptides, thus leading to different strengths of protective or pathogenic immune responses in different individuals against the same pathogen such as HBV (13, 14) . Thus far, the validated T cell epitopes in HBV antigens are still very limited, only 205 CD8 + T cell epitopes and 79 CD4 + T cell epitopes have been defined from HBV proteome by cellular functional experiments, but most are restricted to several common HLA supertypes, such as HLA-A0201, A2402, B0702, DR04, and DR12 molecules, as displayed in the Hepitopes database (15) and other recent reports (6, (16) (17) (18) (19) (20) (21) (22) (23) (24) . Therefore, the current library of validated HBV T cell epitopes cannot cover a broad population carrying highly polymorphic HLA alleles in the indicated geographical regions, and also can not cover broad antigenic targets recognized by HBV-specific CD8 + or CD4 + T cell clones. This limitation thus hampered the development of T cell epitope-based therapeutic vaccine and T cell immunotherapy, and also hampered the clinical precise evaluation of HBV-specific cellular immunity.

To achieve more variable CD8 + T cell epitopes which cover more dominant HLA-A allotypes and span more HBV proteins, this study dedicated to the mapping of CD8 + T cell epitopes derived from overall HBsAg, HBeAg (covering HBcAg), HBx and HBpol proteins, and restricted by a series of high-frequency HLA-A allotypes which gather a total gene frequency of around 95% in Asian population. 187 epitopes restricted by 13 HLA-A allotypes were in silico predicted and selected as candidate epitopes. Of these, 62 epitopes were then functionally validated as real-world epitopes by ex vivo enzyme-linked immunosorbent spot (ELISPOT) assay and in vitro co-cultures, using patients' peripheral blood mononuclear cells (PBMCs). Furthermore, the peptide competitive binding assay and HLA-A/peptide docking as well as molecular dynamic simulation were used to identify the binding affinity and HLA-A cross-restrictions of the 62 epitopes. Finally, a peptide library containing 105 validated epitopes was used to enumerate the peripheral HBV-specific T cells in IFN-g ELISPOT assay for 116 patients with HBV infection.

Patients with HBV infection were recruited in this study from the Division of Hepatitis or Department of Clinical Laboratory at Nanjing Second Hospital. According to the EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection (11) , the CHB patients had clinical, biochemical and virological evidence of chronic hepatitis B infection with HBsAg positiveness for at least 6 months. Three CHB patient groups were enrolled in this study: patients in immune tolerant stage (IT, HBeAg + chronic infection, high viremia but limited liver inflammation), patients in immune active stage (IA, HBeAg + chronic hepatitis, high viremia and high level of alanine aminotransferase), and immune inactive carriers (IC or InA, HBeAgchronic infection, low or undetectable serum viral load and limited liver inflammation with normal level of alanine aminotransferase). In addition, 29 acute resolved patients (R, low or undetectable serum viral load, HBsAg -, and anti-HBcAb + ), 20 patients with liver cirrhosis and 14 patients with liver cancer were also enrolled here. The exclusion criteria for these subjects were the infection with hepatitis C virus, hepatitis A virus or human immunodeficiency virus, and malignant tumor.

The present study was conducted according to the Declaration of Helsinki principles, and the human samples collection and use has been approved by Clinical Ethics Committee of Nanjing Second Hospital (ref: 2018-LY-kt054, 2019-LY-ky011, 2021-LS-ky013). For the validation of putative epitopes using IFN-g ELISPOT assay, 500 whole blood samples from HBV-infected patients were collected from Department of Clinical Laboratory of Nanjing Second Hospital. In this instance, informed consent was waived because these blood samples were the biological specimens obtained from past clinical diagnosis and treatment, but consent was obtained from Clinical Ethics Committee of Nanjing Second Hospital. For the clinical detection of HBV-specific T cells, 116 participants recruited from Division of Hepatitis of Nanjing Second Hospital gave written, informed consent. 3 to 5 mL of whole blood was taken from each patient, and PBMCs were further isolated by density-gradient centrifugation.

T cell epitopes spanning HBsAg, HBeAg (covering HBcAg), HBpol and HBx proteins of HBV and presented by different HLA-A allotypes were in silico predicted using six epitope predication tools and eight types of algorithms (SYFPEITHI, BIMAS, SVMHC-SYFPEITHI/MHCPEP, IEDB-ANN/SMM, NetMHC, EPIJEN). For each HLA-A allotype and each protein, one to five 9-mer and 10-mer peptides with the highest score (highest affinity) as predicted by at least two tools were selected as candidate epitopes for further validation. This study mainly focused on adr and adw serotypes and B, C genotypes of HBV, which are common in Chinese population, and also took A and D genotypes into account. The entire amino acid sequences of each protein from different genotypes were obtained from UniProt database and aligned in Figure S1 .

The peptides were synthesized from China Peptides Co., Ltd with a purity of > 95% as defined by HPLC purification and mass spectrometry and were used in cellular functional experiments. Lyophilized peptides were reconstituted at a stock concentration of 2 mg/mL in DMSO-PBS solution and stored in aliquots at -80°C.

Peripheral blood samples from patients with HBV infection were collected from Department of Clinical Laboratory at Nanjing Second Hospital and processed into PBMCs. The predicted epitopes restricted by the indicated HLA-A allotypes were grouped into several peptide pools (10 epitopes/pool, 10 mg/ epitope/mL), and co-cultured with PBMCs (2×10 5 /well/peptide pool) in 96-well plates coated with anti-human IFN-g for 20 h followed by IFN-g ELISPOT assay, according to manufacturer's instructions (Dakewe Biotech, Shenzhen, China). In parallel, negative control well (PBMCs alone) and positive control well (PBMCs with phytohemagglutinin, PHA, 2.5 mg/mL) were also performed. Notably, in each negative control well, DMSO was supplemented to make its concentration equal to the peptide pool/ PBMCs co-culture well. The spot forming units (SFUs) were imaged and enumerated. Positive T cell response was defined according to the criterion as follows: (SFUs in peptide well -SFUs in negative control well) ≧ 5, while SFUs in negative control well was 0-5; or (SFUs in peptide well)/(SFUs in negative control well) ≧ 2, while SFUs in negative control well was > 5. When the peptide pool can significantly stimulate patient's PBMCs producing IFN-g, the PBMCs were re-collected from the same individual, then cocultured with each epitope peptide in the positive peptide pool and followed by IFN-g ELISPOT assay to identify whether the indicated epitope peptide inducing T cell responses.

Meanwhile, for the patients with positive T cell responses in IFN-g ELISPOT assay, HLA-A alleles were identified using polymerase chain reaction-sequencing-based typing (PCR-SBT) method, the gold-standard method recommended by the International HLA Work Group. Primers as described (25) were synthesized by Sangon Biotech Co., Ltd (Shanghai) and displayed in Table S1 . The DNA from exon 1 to exon 3 of HLA-A was amplified in PCR using primer combination A1/A3 followed by sequencing using primer combination A2F/A2R for exon 2 and A3F/A3R for exon 3. The sequencing data were aligned with the sequences in the HLA database and analyzed using Lasergene software.

Briefly, PBMCs from the patients with HBV infection were prepared, then seeded in 96-well plates (4×10 5 PBMCs/well) and incubated with a single validated epitope peptide (VEP) (20 mg/mL) which presented by the HLA-A allotypes of the indicated patient as in silico predicted, PHA (10 mg/mL) or no peptide in RPMI1640 culture medium with 10% FBS for 7 days at 37°C, 5% CO 2 incubator. Recombinant human IL-2 (20 IU/mL) was added at day 3. On day 7, the corresponding peptide (40 mg/mL) or no peptide (negative control) was added again for another 16-hour co-culture. Then, BFA/Monensin mixture (eBioscience) was added to the cells and co-cultured for another 6 hrs. After that, cells were harvested, washed and blocked with anti-CD16/CD32 (eBioscience) for 20 min, then stained with FITC-labeled antihuman CD3 and APC-labeled anti-human CD8a monoclonal antibodies (mAbs, Biolegend) for 30 min at 4°C. After washing, cells were fixed and permeabilized following the protocol and were further stained with PE-labeled anti-human IFN-g (BD Bioscience) for 30 min at 4°C followed by flow cytometry analysis. The frequencies of IFN-g + cells in CD3 + /CD8 + populations were calculated.

The structure of HLA-A used for receptor was obtained in two ways. For HLA molecules with different binding conformations in world Protein Data Bank (PDB, http://www.wwpdb.org/), such as HLA-A1101, all the matching structures were collected using the mmseqs2 method in PDB (26) . For HLA molecules without crystal structure in PDB, such as HLA-A3101, structures based on homology modeling were selected as receptors, using the Advanced Homology Modeling functionality in Biologics (Schrödinger 2020-4 release).

Since it is difficult to find the HLA-A structures presenting the HBV peptides, a reasonable docking conformation was obtained by the following two ways. As for structure collected from PDB, the peptide sequence in the complex with indicated HBV peptide was compared and the most similar complex based on the properties of main anchor residues was selected. Then, the original peptides in the peptide-HLA complex were mutated manually into the indicated HBV peptides. As for modelled structures, CodockPP server (27) (http://codockpp.schanglab. org.cn/index.php) was used to dock the peptides which derive from HLA modeling templates with them. The best docking poses according to Ligand RMSD are retained for subsequent scanning calculations (28) . Some cases, such as HLA-A1101, due to the properties of the amino acids of its peptide, it cannot be mutated into HBV peptides. The peptide docking functionality in Biologics and molecular dynamics simulation functionality in Desmond (Schrödinger 2020-4 release) were used to get reasonable binding conformation. And the Generalized Bonn surface area based on molecular mechanics (MM-GBSA) in Prime (Schrödinger 2020-4 release) were used to obtain binding free energy.

Residue Scanning makes a specified list of mutations and then performs MM-GBSA calculations of the bound and unbound state for each system for both the wild type and the mutant. The predicted change in binding affinity is calculated using the equation and thermodynamic cycle as below:

Thermodynamic cycle for calculating the net DDG free energy difference between binding the wild-type protein P and the mutant protein P'. E is the calculated energy of each protein or complex after refinement (29).

HMy2.CIR cell line was purchased (Zhongqiao xinzhou Biotech, Shanghai) and maintained in complete IMDM medium with 10% FCS and 1% penicillin/streptomycin. Total mRNA was extracted from PBMCs of healthy donor with the indicated HLA-A alleles by RNAprep Pure Hi-Blood Kit (TIANGEN, Beijing, China), and the cDNA was generated by using HiScriptII1 st Strand cDNA Synthesis Kit (Vazyme, China) at RT. Each HLA-A allele was then amplified in PCR using the primer combination AF/AR, and the 5' and 3' ends of PCR product contained the same sequences as that of the linearized vector. Linearized pcDNATM3.1/myc-His (-)AMCS was amplified in PCR using the primer combination P-1F/P-1R. Finally, the routine construction of pcDNATM3.1 recombinant plasmids were obtained with ClonExpressII One Step Cloning Kit (Vazyme, China).

Primers were synthesized by Sangon Biotech (Shanghai) and displayed in Table S1 . After electrotransfection, the cell lines stably expressing HLA-A molecule were screened by G418, and then stained with PE-anti-HLA-ABC (clone W6/32, eBioscience), FITC-anti-HLA-A24 (clone 17A10, MBL) or PEanti-HLA-A2 (clone BB7.2, BD Bioscience). The resulting cells highly expressing the indicated HLA-A allotypes were positively sorted using a fluorescence activated cell sorter (FACS, BD FACSAriaIISORP), and followed by cell pure culture and gene sequencing analyses.

A set of fluoresce-labeled reference peptides (positive-control peptide) were synthesized with a purity of >99% by Sangon Biotech and stored at 4°C, such as FLPSDK(FITC)FPSV for A0201, A0203 and A0206 (30) , YVNVNK(FITC)GLK for A1101 and A3303 (31), EYLVSK(FITC)GVW for A2402 (32) , ATFQFK (FITC)VER for A3101, A1102 and A0301 (33), KLPDDFK (FITC)GCV for A0207 (34) , YLEPAK(FITC)AKY for A0101 (30) , and ASRELK(FITC)VSY for A3001 (identified in house). Then the competitive peptide binding assay was performed as described with minor modifications (30, 35) . Briefly, the HMy2.CIR cell lines expressing the indicated HLA-A molecule were washed with acid buffer (0.131M citric acid and 0.061M sodium phosphate Na 2 HPO 4 , PH3.3, 0.22 mm filtered) for 1 min, and immediately neutralized by IMDM medium containing 0.5% BSA. After washing, the cells were seeded into 96-well U culture plate (1×10 5 cells/100 mL/well) with b 2 -m (1 mg/mL). Then 25 mL unlabeled competitor peptide (5 mM or 15 mM) and 25 mL corresponding FITC-labeled reference peptide (300 nM) were added into the well and co-incubated for 24 h at 4°C. In parallel, no peptide control well (cells alone) and positive control well (cells with FITC-labeled reference peptide) were also performed.

The plate was centrifuged at 600 rpm for 5 min at room temperature (RT). Cells were washed twice with 100 mL cold 0.5% BSA-PBS. Finally, cells were resuspended with 150 mL PBS and analyzed with flow cytometry. Sample % is the percentage of FITC + cells in the experiment well, while the background % is the percentage of FITC + cells in the no peptide control well, and the max % is the percentage of FITC + cells in the positive control well. Competitive binding (%) = [1-(sample %background %)/(max %background %)] × 100%. IC50 is the concentration of unlabeled competitor peptide required to inhibit the binding of FITC-labeled reference peptide by 50%, which is calculated from the competitively binding inhibition (%) of the sample at 5 mM and 15 mM. Binding affinity of unlabeled peptide with the indicated HLA-A molecule is assessed by IC50. IC50<5mM (5mM inhibition >50%) means high binding affinity, 5mM<IC50<15mM (5mM inhibition<50%, but 15mM inhibition >50%) means intermediate binding affinity, IC50>15mM means low or no binding affinity (5mM inhibition 20-50% or 15mM inhibition 30-50% means low binding affinity; 5mM inhibition <20% or 15mM inhibition <30% means no binding affinity).

The CD8 + T cell epitopes validated in house were integrated with the CD8 + T cell epitopes reported previously to establish an HBV-specific antigenic peptide library containing 105 epitopes. These epitopes are presented by 13 predominant HLA-A allotypes which have a total gene frequency of around 95% in Chinese and Northeast Asian populations and were arranged into seven peptide pools (15 epitopes/pool) to establish the poolarray IFN-g ELISPOT assay for the enumeration of active/ memory HBV-specific T cells in peripheral blood.

Fresh peripheral blood samples from in-patients with chronic hepatitis B were collected in the Division of Hepatitis at Nanjing Second Hospital and processed into PBMCs followed by IFN-g ELISPOT assay according to manufacturer's protocols (Dakewe Biotech). Notably, the PBMCs from each patient were cocultured in 96-well plates with 7 peptide pools (2×10 5 cells in each well with one peptide pool, 2 mg/peptide/well) for 20 hrs. In parallel, the positive control well with PHA (0.25 mg/well) and negative control well with PBMC alone were carried out. SFUs/ 2×10 5 PBMCs = (Sum of actual spot numbers in the 7 experimental wells) -(Sum of background spot numbers in the 7 experimental wells). When the actual spot number in the indicated experimental well is less than that in the negative control well, the actual spot number is taken as the background spot number of the indicated experimental well. When the actual spot number in the indicated experimental well is equal to or greater than that in the negative control well, the spot number in the negative control well is taken as the background spot number in the indicated experimental well. The clinical baseline features and the real-time data from clinical laboratory were also collected for each patient.

Statistical analyses were performed using GraphPad Prism 9 (GraphPad, La Jolla, CA, USA). Data were expressed as median (range) or mean (± standard error of mean, SEM). One-way analysis of variance (ANOVA) (for gaussian data) or Kruskal-Wallis test (for non-paprametric data) was performed when analyzing more than two groups. Then, a Mann-Whitney (non-parametric) test was used for the analysis of HBV DNA and Alanine aminotransferase (ALT) means, SFUs, HBsAg and HBeAg medians between two groups. The c2 tests were used for the comparison of Anti-HBc IgM positive/negative categorical data across groups. Pearson (for gaussian data) correlation tests were performed to analyze correlation between peptide competitive binding experiment and bioinformatics analysis. For the analysis between stratified patient groups, multivariate linear regression analysis was performed. All statistical analyses were based on 2-tailed hypothesis tests with a significance level of p<0.05.

The potential epitopes derived from four HBV proteins (HBsAg, HBeAg, HBpol, HBx) and restricted, respectively, by 13 HLA-A allotypes were virtually predicted, by using epitope prediction tools and algorithms. The thirteen high-frequency HLA-A allotypes (HLA-A1101, A2402, A0201, A0207, A3303, A0206, A3001, A0203, A3101, A1102, A0101, A2601, A0301) cover over 95% Chinese and Northeast Asian populations with a gene frequency greater than 1% for each allele (http://www. allelefrequencies.net). For each HLA-A allotype and each protein, the top one to five 9-and 10-mer peptides with high affinity were chosen as best putative epitopes according to these criteria: the binding affinity exceeding the antigenic criteria of at least two algorithms; the ranking in top 1 to 5 as predicted by at least two algorithms. In addition, the diversities across virus genotypes and serotypes were also taken in account. Totally, 187 epitopes were selected as candidate epitopes with the number of 35, 28, 37 and 24 from HBsAg, HBeAg, HBpol, and HBx protein, respectively. Of the 187 predicted epitopes, 63 epitopes are common epitopes presented by several HLA-A allotypes as in silico predicted, so totally only 124 epitopes need to be synthesized as peptides for further investigation (Table S2 ).

Since HBV-specific CD8 + T cells can be detectable in only about 50% CHB patients' PBMCs by ex vivo analyses as reported (36), here PBMCs were collected from a large cohort of HBV infected patients. During the 20-hour ex vivo co-incubation and ELISPOT assay, the candidate epitope peptide that can stimulate PBMCs to obviously produce IFN-g was identified as validated epitope peptide (VEP), implying the presences of the peptide-specific memory or activated T cell clones in patient's peripheral blood. Totally, 500 PBMCs samples were ex vivo tested with the peptide pools of 124 candidate epitopes, and 106 samples displayed positive T cell responses in the first-round ELISPOT assay. Of the 106 patients, 56 patients were re-enrolled and their PBMCs were re-collected followed by co-culture with each type of epitope peptides from the peptide pools which induced positive T cell responses in the first-round ELISPOT assay. After two rounds of ELISPOT assays, the immunogenicity of 62 candidate epitopes was finally validated ( Table 1) . The representative ELISPOT spot plots for each epitope were displayed in Figure 1 . The clinical data were collected, and HLA-A genotyping were performed for the 56 patients (Table S3) . Furthermore, the epitopes validated by IFN-g ELISPOT assay were assessed for their in vitro capacity to induce CD8 + T cell activation by co-cultures with patients' PBMCs for 7 days and followed by IFN-g intracellular staining. The frequencies of IFN-g + cells in CD3 + /CD8 + or CD3 + /CD8populations were analyzed by flow cytometry. When the frequency of IFN-g + cells in the co-culture well was two-fold greater than that of negative control well (PBMCs alone), the epitope peptide in the coculture was defined as the immunogenic epitope that can induce CD8 + or CD4 + T cell responses as described (50) . Totally, 25 epitope peptides were tested using the PBMCs from 19 patients with matching HLA-A alleles. Each epitope peptide was confirmed to induce positive CD8 + T cell responses in the PBMCs from one, two or three patients. But interestingly, 13 of the 25 CD8 + T cell epitope peptides simultaneously induced CD4 + T cell responses 5with a two-to six-fold increase in IFN-g + /CD3 + / CD8 -T cell frequency in the in vitro peptide-PBMCs cocultures (Figures 2, S2 ).

The entire amino acid sequences of HBsAg, HBeAg, HBx and HBpol proteins from HBV C, B, A and D genotypes were screened for the CD8 + T cell epitopes restricted by the thirteen prevalent HLA-A allotypes in China. These sequences were obtained from UniProt database and derived from the HBV strains reported in China or Northeast Asia. In the in silico prediction, the overall sequences of target protein from each HBV genotype were screened. The distinct epitopes between different genotypes and serotypes were also selected as candidate epitope peptides for further validation ( Table S2 ). The fourth (51) . Multiple sequence alignments were performed using the ClustalW method in the Molecular Evolutionary Genetics Analysis software (MEGA7, version 1.0.0.0) (52) , and positions where a gap was neglected. Then, GeneDoc software (version 2.7.0) was used to analyze the alignment results to obtain the conservative region of these sequences. The conservative properties of each amino acid in each protein were judged by the threshold of 100%, 95%, 80%, and the amino acids were highlighted in different colors (100%: red, ≥95%: yellow, ≥80%: black in gray background, and <80%: black in white background) ( Figure S3 ). Finally, 62 epitopes validated in this study were classified into three categories according to its conservation (≥95%, 80-95%, <80%) and displayed in the fifth column of Table 1 . Conservation ≥95%: each amino acid in the epitope with the conservative properties of 95-100%; Conservation 80-95%: at least one amino acid in the epitope with the conservative properties of ≥80% and <95%; Conservation <80%: at least one amino acid in the epitope with the conservative properties of <80%. Of 62 validated epitopes, 10 epitopes in HBpol and 3 epitopes in HBsAg have the conservative properties of <80%.

To further identify HLA-A restrictions of the validated peptides, the binding affinity between VEPs and corresponding HLA-A allotypes were analyzed by using bioinformatics methods, such as residue scanning, molecular docking and dynamic simulation. The three-dimensional structures of HLA-A allotypes were selected or constructed from PDB, which would be used as protein-protein interaction analysis. Then the binding motifs of all peptide-HLA complexes were analyzed. The peptide sequence in the complex with the indicated HBV peptide was compared and the most similar complex based on the properties of main anchor residues was selected. For HLA-A molecules that do not have peptide binding conformation, peptide docking, and dynamics simulation were used to achieve a reasonable binding conformation. Then physics-based scoring was used to calculate free energies of binding for peptide-HLA complex, which could characterize the strength of the bonding. In general, the greater the negative value is, the stronger the bond is. D Affinity values of less than 3 Kal/mol were considered to have a better affinity than the Bond Peptide in PDB of HLA. If the D Affinity score was greater than 3 Kal/mol, it would be considered that the HBV peptide might not bind to the corresponding HLA-A molecule (29) . While Prime Affinity and MM-GBSA score represented the affinity score of HBV peptide to HLA-A molecule, it was generally believed that the smaller the score, the higher the Affinity, which could be used for ranking (29) . The representative schematic diagrams of the interaction between HBV peptide and HLA-A molecule were displayed in Figure S4 .

Here, 45 HBV epitope peptides validated in house were analyzed for their cross-binding affinity with corresponding HLA-A allotypes. Each peptide was tested with several HLA-A allotypes. The calculation results were displayed in Table S4 and ranked in Table 1 .

A B FIGURE 1 | 62 candidate HBV epitopes were validated as real-world T cell epitopes by IFN-g ELISPOT assay using patients' PBMCs. The PBMCs from 500 HBV infected patients were co-cultured 20 h with the peptide pools of 124 candidate epitopes. Of which, 106 PBMCs displayed positive T cell responses in the firstround IFN-g ELISPOT assay. Then PBMCs were re-collected from 56 patients and co-cultured with single epitope peptide of the peptide pools positive in the firstround IFN-g ELISPOT assay and followed by the second-round ELISPOT assay. were generated firstly, sorted by flow cytometry, and identified by gene sequencing. The purity of these transfected HMy2.CIR cell lines was 80% to 94% after sorting ( Figure S5 ). Subsequently, the unlabeled epitope peptides of HBV competed with fluorescently labeled reference peptides in the binding with HLA-A molecules onto transfected cell lines for 24 hours. Here, twelve prevalent HLA-A allotypes were tested with totally 62 HBV epitope peptides validated in house. As shown in the line diagrams of flow cytometry, most competitor peptides could result in a left shift of the cell fluorescent peak from reference peptide ( Figure S6 ), implying the efficient binding of epitope peptides with associated HLA-A molecules. Table 2 ). In addition, although results from peptide competitive binding experiments were partially inconsistent with the data from bioinformatics analysis ( Table 1) , the correlation coefficient between the two methods was confirmed, r=-0.248 at 5 mM inhibition or -0.255 at 15 mM inhibition, p <0.05 (Figure 3 ).

In order to monitor the HBV-specific cellular immune function for the broad patients carrying distinct HLA-A alleles, 62 epitopes validated here were integrated with other 43 CD8 + T cell epitopes which were mostly presented by the relatively lowfrequency HLA-A allotypes (A0101, A1102, A2601 and A0301) and reported by other researchers or in silico predicted but confirmed by peptide competitive binding experiments using transfected HMy2.CIR cell lines in this study. Of these epitopes, each one can be cross-bound by several ones of the 13 most predominant HLA-A allotypes in Chinese and Northeast Asian populations. The validated epitope peptides restricted by each HLA-A allotype were exhibited in Table 3 . Meanwhile, we cannot exclude the possibility that these antigenic peptides can also be presented by other HLA-A allotypes beyond the 13 prevalent ones here.

Then, IFN-g ELISPOT assay using the 105 validated peptides was performed to enumerate the memory or active HBV-specific T cells (mainly CD8 + T cells) in the peripheral blood of 116 patients with HBV infection. The clinical baseline features of enrolled patient cohort were displayed in Table 4 . In order to assess the correlation of HBV-specific T cell response with clinical parameters, patients were grouped into three subsets according to IFN-g + SFU levels: 25% of the cohort with low SFU level (0-19), 50% of the cohort with intermediate SFU level , and 25% of the cohort with high SFU level (74-502). As shown in Table 5 , serum HBeAg levels were detected lower in the inter-level SFUs group than in the high-level SFUs group (Median:0.12 vs 2.87, p=0.023). No significant difference on serum viral load, ALT, HBsAg, or anti-HBc IgM parameters was found across the SFUs groups. Moreover, multivariate linear regression analysis was performed for these items. The SFUs (assigned: continuous variable) was used as the dependent variable, while HBV DNA, ALT, HBsAg, HBeAg and Anti-HBc-IgM (all as classification variables) were used as independent variables. The results showed that the regression equation was tested as F = 3.112, p = 0.004. indicating that the regression model was qualified. The collinearity was evaluated by variance inflation factor. The P values of DNA, ALT, HBsAg, HBeAg and Anti-HBc-IgM were 0.300, 0.898, 0.000, 0.834 and 0.756, respectively. HBsAg levels significantly correlated with SFUs levels. In addition, age, different diseases (R, CHB, LC and HCC) and different stages of CHB (IT, IA and IC) were also used as independent variables in different regression models, no correlation with SFUs levels was found.

Although numerous studies have confirmed the important influences of host HBV-specific T cell immunity on the disease progression (5) (6) (7) 53) , antiviral efficacy (8) and recurrence after therapy discontinuation (10, 12) , the clinical uses of T cell epitope-based therapeutic vaccines and HBV-specific T cell detection are still limited. This is mainly contributed to the high diversity of HLA alleles and T cell epitopes, the key factors that must be taken in account when preparing an epitope vaccine or T cell detection kit. By now, only round 205 CD8 + T cell epitopes have been validated as summarized in our recent review. Of which, 121 (59.0%) epitopes are restricted by HLA-A0201, A2402 or B0702. The remainder are restricted mainly by 12 HLA-A, 5 HLA-B and 1 HLA-C supertypes (24) . Obviously, the current library of validated T cell epitopes of HBV cannot cover the major populations in an indicated geographic region. More efforts are required to identify more T cell epitopes restricted to the regional prevalent HLA supertypes, especially for the HLA alleles prevalent in Asian populations with a high HBV incidence (54) .

This study focuses on three points which different from previous studies: firstly, screening the HBV antigen epitopes presented by a series of high-frequency HLA-A allotypes in Asia. Each allotype has a gene frequency of >1% in Chinese and Northeast Asian populations. Totally, 13 kinds of predominant HLA-A allotypes were selected here and gather a total HLA-A allele frequency of around 95.5% in Chinese population while 94%, 83%, 80%, 70% and 63% in Northeast Asia, Southeast Asia, Europe, South America, and North America populations, respectively (http://www.allelefrequencies.net). The entire amino acid sequences of HBsAg, HBeAg, HBx and HBpol proteins from HBV C, B, A and D genotypes were screened for the CD8 + T cell epitopes restricted by the thirteen HLA-A allotypes, using the combined system of in silico prediction first and cellular functional validation later, an efficient, lowcost, and currently wide-used system for T cell epitope screening. Secondly, as known, one T cell epitope usually can be presented by several HLA allotypes with distinct binding affinity, named HLA cross-restriction. However, identifying the HLA restriction and cross-restriction of a T cell epitope is usually difficult due to the lack of standard methods. Therefore, most HBV T cell epitopes reported previously have not been elaborated for their HLA restriction, especially the cross-restriction by multiple HLA allotypes. Some epitopes have been elucidated only by in silico prediction or mere guesswork according to patient's HLA serotypes or genotypes, such as HLA-A2 restricted epitopes (44, 55, 56) , A24 (43), A3 (37, 47) , A11 (37, 57) and A33 (41) restricted HBV epitopes. Thus this study not only validated the immunogenicity of 62 HBV T cell epitopes using ex vivo and in vitro cellular functional experiments, but also further identified their HLA-A cross-restrictions using multiple approaches. Thirdly, this study provided a library of HBV antigen CD8 + T cell epitopes that not only can target as many as 105 HBVspecific CD8 + T cell clones to reflecting patient's T cell immune function, but also fits to the herd HLA genetic characteristics of Chinese and Northeast Asian populations, thus can be used to prepare ELISPOT or FluoroSpot kit and monitor HBV-specific T cell responses for broad patients. In order to elucidate the HLA-A cross-restriction of 62 validated epitopes, the data from five approaches were taken into account comprehensively in this study as displayed in Table 1 : in silico predicted HLA-A restriction by five prediction algorithms; ex vivo ELISPOT-positive patient's HLA-A genotype; in vitro CD8 + T cellsactivating patient's HLA-A genotype; HLA/peptide docking and molecular dynamic simulation; and peptide competitive binding assay using HMy2.CIR cell lines expressing the indicated HLA-A allotype. Additionally, the PBMCs from patients carrying homologous HLA-A alleles were also used to identify the HLA-A restriction of partial epitopes by ex vivo ELISPOT assay, and 24 epitopes were confirmed to be presented by the indicated HLA-A allotype. Of note is that data from theoretical prediction were partially inconsistent with the ELISPOT-positive patients' HLA-A genotypes. For example, P51 was supposed to be an HLA-A2402 restricted epitope as predicted, but it induced positive T cell responses in the PBMCs from an HLA-A0201 + /A0207 + patient. Similar data for P77, 78, 95, 103, and 108 were also observed. These discordant results should be contributed by the inaccuracy of theoretical prediction, the small cohort of HLA-A matched patients, and the technical pitfall of ELISPOT assay. In our experiences, only around half of predicted epitopes can be validated finally as immunogenic epitopes in cellular functional experiments. In another hand, the real-world epitope can induce T cell response only in partial HLA-matched patients, but not in all HLA-matched patients, particularly in the ex vivo ELISPOT assay. Therefore, in this case, we further evaluated the binding affinity of the indicated epitopes with associated HLA-A allotypes, such as P51 with HLA-2402, A0201 and A0207, using HLA/peptide docking and molecular dynamic simulation, and peptide competitive binding assay. The prime-affinity calculated from bioinformatics analysis displayed the strongest binding of P51 with HLA-A2402 (-243.243), and slightly stronger binding with HLA-A0201 (-160.656) than with HLA-0207 (-142.36) ( Table S4 ). In general, more negative the prime-affinity, stronger the bond. In parallel, peptide competitive binding showed the intermediate affinity of P51 with HLA-A2402 (39.97% and 52.50% inhibition at 5mM and 15mM, respectively), low affinity with HLA-A0207 (43.00% inhibition at 5mM or 15mM), and no affinity with HLA-A0201 (2.00% and 4.50% at 5mM and 15mM, respectively) ( Table 2) . We also can find partial discordant results between bioinformatics analysis and peptide competitive binding, such as P51, P103, P108, et al, but Pearson correlation tests confirmed the correlation coefficient of data from the two methods. Taken together, although not perfect, we provided the original theoretical and experimental data about the HLA-A allotypes associated with each in-house validated epitope and elucidated their HLA-A cross-restrictions to some extent.

Of note is that 13 of the 25 CD8 + T cell epitope peptides simultaneously induced CD4 + T cell responses in the 7 days of cocultures of peptide with patient's PBMCs, as detected by IFN-g intracellular staining and flow cytometry (Figure 2) . Similar results were also found in our previous study about T cell epitopes screening of SARS-CoV-2, in which 44 (36.66%) of the 120 validated CD8 + T cell epitope peptides simultaneously elicited CD4 + T cells with a two-to six-fold increase in IFN-g + /CD3 + /CD8 -T cell frequency in the 14 days of DC-peptide-PBL cocultures. However, after immunization with the 31 validated CD8 + T cell epitope peptides cocktail, only very weak CD4 + T cell responses were found in the HLA-A2/DR1 transgenic mice, as detected by IFN-g intracellular staining (50) . These data may suggest that a high concentration of short epitope peptides (9-or 10-mer, 20 mg/ mL) may also be presented to CD4 + T cells by HLA class II molecules onto DC and B cells in the 7-14 days of coculture system but not under in vivo conditions. The underlying mechanism remains to be further elucidated. In this study, the 62 T cell epitopes presented by HLA-A allotypes were validated by ex vivo IFN-g ELISPOT assay using patient's PBMCs. Of which, whether some epitope peptides also stimulate CD4 + T cell to producing IFN-g in the 20 hours of ELISPOT assay remains unclear.

The clinical detection of host HBV-specific T cells is still very limited, since no standard T cell epitope library covering broad patients is available thus far. Most studies have utilized panels of overlapping peptides (OLPs) spanning overall HBV antigens (peptide scanning) rather than functionally validated epitope peptides (VEPs) in the ELISPOT or FluoroSpot assay for HBVspecific T cell enumeration or in the mass cytometry for T cell functional phenotype analysis, after ex vivo co-culture of OLPs pools with host lymphocytes (12, (58) (59) (60) (61) . Only few researchers used a small amount of VEPs for the patient cohort with matching HLA allotype (62) . As known, OLPs are not realworld proven T cell epitopes, most of them are pseudo-epitopes with unknown HLA restrictions, thus should not be a standard epitope library. More importantly, due to the large amount of OLPs spanning overall HBV polyproteins, peptide scanning is a high-cost and laborious method. For CD8 + T cell epitope, HBsAg, HBeAg, HBx and HBpol contain 131, 68, 49, and 279 OLPs (9-mer), respectively, when overlapping 6 amino acids.

This study makes efforts to explore a potent alternative way to detect HBV-specific T cells. We set a peptide library of 105 VEPs which cover most prevalent HLA-A allotypes and majority patients in Chinese and Northeast Asian populations. Of course, the current HLA-A restricted VEPs library cannot decipher global CD8 + T cell responses against HBV infection. We will further screen the epitopes presented by prevalent HLA-B and C allotypes to enrich the VEPs libraries for broader representation of target T cell clones. So currently we cannot perform the methodological comparison with the OLPs-used ELISPOT assay, although OLPs also can not define host global T cell responses. Whether using VEPs will provide more information than the use of OLPs remains to be demonstrated later. But the initial data from IFN-g ELISPOT assay using the 105 HLA-A restricted VEPs displayed significant differences in the stratification analysis of HBV-specific T cell responses for 116 HBV infected patients. Multivariate linear regression analysis confirmed the significant correlation between HBsAg levels and SFUs levels. These conclusions mostly are consistent with previous researches using OLPs (19, (63) (64) (65) (66) . To get the more convincing and ample evidences, we will further enrich the VEPs library and expand the patient cohort to decipher the correlations of HBV-specific T cell responses with clinical and laboratory features. Taken together, this study functionally validated 62 HBV CD8 + T cell epitopes and identified their cross-restriction by twelve prevalent HLA-A allotypes using multiple approaches. A peptide library of 105 VEPs covering the herd polymorphism of HLA allotypes in Chinese and Northeast Asian populations were achieved and followed by the evaluation of HBV-specific T cell responses for HBV infected patients using ELISPOT assay. Overall, this study provides novel HBV CD8 + T cell epitopes for the design and development of therapeutic vaccines inducing antiviral CD8 + T cell responses, and also provides an alternative way beyond OLPs for clinical test of HBV-specific T cell response.

The datasets presented in this study can be found in online repositories. The names of the repository/repositories and accession number(s) can be found in the article/Supplementary Material.

The studies involving human participants were reviewed and approved by Clinical Ethics Committee of Nanjing Second Hospital. The patients/participants provided their written informed consent to participate in this study.

JL, JQ, and CS designed and supervised the research. YD and ZZ performed the main experiments of this study. XYL and XM performed the bioinformatics analysis. CZ and XJ assisted in the in silico prediction of T cell epitopes and set up the functional validation experiments of candidate epitopes using patient's PBMCs and IFN-g ELISPOT assay. XTL collected patients' blood samples, prepared PBMCs and performed HLA-A genotyping. YW assisted in the generation of HMy2.1CIR cell lines expressing indicated HLA-A allotypes and reviewed the HBV T cell epitopes reported previously. CS and YD organized the whole data and wrote the manuscript with discussions from all authors. All authors contributed to the article and approved the submitted version. HBx and HBpol in HBV genotype A, B, C and D were collected from HBVdb database. Multiple sequence alignments were performed and analyzed to obtain the conservative regions of these sequences in a genotype-dependent way. The conservative properties of each amino acid in each protein were judged by the threshold of 100%, 95%, 80%, and the amino acids were highlighted in different colors (100%: red, ≥95%: yellow, ≥80%: black in gray background, and <80%: black in white background).

Supplementary Figure 4 | The binding pattern between the main anchor residues of HBV epitope peptides with HLA-A molecules. The conformational interaction between P2, PW and the whole length of HBV epitope peptide (FLWEWASVR), (MMWYWGPSL) and (STLPETTVVR) with HLA-A0201 (PDB ID: 5F9J), A2402 (PDB ID: 2BCK) and A1101 (PDB ID: 5WKF), respectively, were displayed in 3D structures of peptide-binding groove of HLA-A molecules.

Supplementary Figure 5 | Hmy2.CIR cell lines expressing indicated HLA-A allotypes. The transfected Hmy2.1 CIR cell lines expressing HLA-A2402, A0207, A0201, A0203, A0206, A0101, A1101, A3101, A3303, A3001, A1102 or A0301 were generated, respectively, and stained with FITC-anti-HLA-A24, PE-anti-HLA-A2 or PE-anti-HLA-ABC, then sorted by flow cytometry. The purity of these transfected HMy2.CIR cell lines was 80% to 94% after sorting.

Supplementary Figure 6 | Binding affinity analysis of 62 validated HBV epitope peptides with corresponding HLA-A allotypes using peptide competitive binding assay. A series of unlabeled HBV epitope peptides were co-incubated with fluorescently labeled reference peptides and transfected HMy2.CIR cell lines expressing the indicated HLA-A allotypes. Then the competitively binding (%) of each HBV epitope peptide at 5mM and 15mM was calculated by measuring the percentage of fluorescence-positive HMy2.CIR cells. Blue line and purple line represented the line diagram of cell fluorescence strength under 5mM and 15mM HBV epitope peptide, respectively. Gray filled and red line represented the cell maximal fluorescence (cells with FITC-labeled reference peptide) and no peptide control (cell background fluorescence with 1640 medium alone), respectively.

World Health Organization

Countdown to 2030: Eliminating Hepatitis B Disease

Mapping the Interactions of HBV cccDNA With Host Factors

Immunobiology of Hepatitis B Virus Infection

Immunopathogenesis of Hepatitis B Virus

Multifactorial Heterogeneity of Virus-Specific T Cells and Association With the Progression of Human Chronic Hepatitis B Infection

Genetic and Phenotypic Difference in CD8(+) T Cell Exhaustion Between Chronic Hepatitis B Infection and Hepatocellular Carcinoma

Development of Direct-Acting Antiviral and Host-Targeting Agents for Treatment of Hepatitis B Virus Infection

Intrahepatic CD8(+) T-Lymphocyte Response Is Important for Therapy-Induced Viral Clearance in Chronic Hepatitis B Infection

Discontinuation of Oral Antivirals in Chronic Hepatitis B: A Systematic Review

Clinical Practice Guidelines on the Management of Hepatitis B Virus Infection

Hepatitis B Virus-Specific T Cells Associate With Viral Control Upon Nucleos (T)Ide-Analogue Therapy Discontinuation

Association of HLA-Alleles With the Immune Regulation of Chronic Viral Infections

Clinical Relevance of HLA Gene Variants in HBV Infection

Hepitopes: A Live Interactive Database of HLA Class I Epitopes in Hepatitis B Virus

Analysis of Epitope-Based Vaccine Candidates Against the E Antigen of the Hepatitis B Virus Based on the B Genotype Sequence: An In Silico and In Vitro Approach

Immune Responses of Human T Lymphocytes to Novel Hepatitis B Virus-Derived Peptides

CD8(+) T-Cell Response-Associated Evolution of Hepatitis B Virus Core Protein and Disease Progress

Phenotype and Function of HBV-Specific T Cells Is Determined by the Targeted Epitope in Addition to the Stage of Infection

Hepatitis Delta Virus Acts as an Immunogenic Adjuvant in Hepatitis B Virus-Infected Hepatocytes

In Vivo Therapeutic Effects of Affinity-Improved-TCR Engineered T-Cells on HBV-Related Hepatocellular Carcinoma

TNF-Alpha/IFN-Gamma Profile of HBV-Specific CD4 T Cells Is Associated With Liver Damage and Viral Clearance in Chronic HBV Infection

Discovery and Selection of Hepatitis B Virus-Derived T Cell Epitopes for Global Immunotherapy Based on Viral Indispensability, Conservation, and HLA-Binding Strength

A Systematic Review of T Cell Epitopes Defined From the Proteome of Hepatitis B Virus. Vaccines (2022)

Sequence-Based Typing of HLA: An Improved Group-Specific Full-Length Gene Sequencing Approach

RCSB Protein Data Bank: Powerful New Tools for Exploring 3D Structures of Biological Macromolecules for Basic and Applied Research and Education in Fundamental Biology

A Multistage Approach for Global and Site-Specific Protein-Protein Docking

Antibody Structure Determination Using a Combination of Homology Modeling, Energy-Based Refinement, and Loop Prediction

Applying Physics-Based Scoring to Calculate Free Energies of Binding for Single Amino Acid Mutations in Protein-Protein Complexes

Competition-Based Cellular Peptide Binding Assay for HLA Class I

Purification and Characterization of a Naturally Processed Hepatitis B Virus Peptide Recognized by CD8+ Cytotoxic T Lymphocytes

Identification of Hepatitis B Virus-Specific CTL Epitopes Presented by HLA-A*2402, the Most Common HLA Class I Allele in East Asia

The C-Terminal Extension Landscape of Naturally Presented HLA-I Ligands

Screening and Identification of Severe Acute Respiratory Syndrome-Associated Coronavirus-Specific CTL Epitopes

Enhanced Induction of Human WT1-Specific Cytotoxic T Lymphocytes With a 9-Mer WT1 Peptide Modified at HLA-A*2402-Binding Residues

Restoration of HBV-Specific CD8+ T Cell Function by PD-1 Blockade in Inactive Carrier Patients Is Linked to T Cell Differentiation

Human Histocompatibility Leukocyte Antigen-Binding Supermotifs Predict Broadly Cross-Reactive Cytotoxic T Lymphocyte Responses in Patients With Acute Hepatitis

HLA A2 Restricted Cytotoxic T Lymphocyte Responses to Multiple Hepatitis B Surface Antigen Epitopes During Hepatitis B Virus Infection

The Cytotoxic T Lymphocyte Response to Multiple Hepatitis B Virus Polymerase Epitopes During and After Acute Viral Hepatitis

Natural Killer (NK) Cells, and Natural Killer T (NKT) Cells in Patients With Acute Hepatitis B Infection

Identification of Hepatitis B Virus-Specific CTL Epitopes Presented by HLA-A*33:03 in Peripheral Blood Mononuclear Cells From Patients and Transgenic Mice

Recovery of Known T-Cell Epitopes by Computational Scanning of a Viral Genome

Recovery of Functional Cytotoxic T Lymphocytes During Lamivudine Therapy by Acquiring Multi-Specificity

Acute Phase HBV-Specific T Cell Responses Associated With HBV Persistence After HBV/ HCV Coinfection

A Complete Genomic Analysis of Hepatitis B Virus Isolated From 516 Chinese Patients With Different Clinical Manifestations

Rational Design of a Multiepitope Vaccine Encoding T-Lymphocyte Epitopes for Treatment of Chronic Hepatitis B Virus Infections

Cellular Immune Responses to the Hepatitis B Virus Polymerase

HLA-A2 1 Restricted Peptides From the HBx Antigen Induce Specific CTL Responses In Vitro and In Vivo

Multiepitope Peptide-Loaded Virus-Like Particles as a Vaccine Against Hepatitis B Virus-Related Hepatocellular Carcinoma

Screening HLA-A-Restricted T Cell Epitopes of SARS-CoV-2 and the Induction of CD8(+) T Cell Responses in HLA-A Transgenic Mice

HBVdb: A Knowledge Database for Hepatitis B Virus

MEGA7: Molecular Evolutionary Genetics Analysis Version 7.0 for Bigger Datasets

Immunogenicity of Twenty Peptides Representing Epitopes of the Hepatitis B Core and Surface Antigens by IFN-g Response in Chronic and Resolved HBV

Requirements for Global Elimination of Hepatitis B: A Modelling Study

Longitudinal Analysis of CD8+ T Cells Specific for Structural and Nonstructural Hepatitis B Virus Proteins in Patients With Chronic Hepatitis B: Implications for Immunotherapy

High Frequency of Functional Anti-YMDD and -Mutant Cytotoxic T Lymphocytes After In Vitro Expansion Correlates With Successful Response to Lamivudine Therapy for Chronic Hepatitis B

Pools of Lipidated HTL-CTL Constructs Prime for Multiple HBV and HCV CTL Epitope Responses

Simultaneous Assessment of Cytotoxic T Lymphocyte Responses Against Multiple Viral Infections by Combined Usage of Optimal Epitope Matrices, Anti-CD3 mAb T-Cell Expansion and "RecycleSpot

Memory T Cells Specific for HBV Enumerated by a Peptide-Based Cultured Enzyme-Linked Immunospot Assay in Healthy HBV-Vaccinated Subjects

OX40 Stimulation and PD-L1 Blockade Synergistically Augment HBV-Specific CD4

T Cells in Patients With HBeAg-Negative Infection

Identification of the Association Between HBcAg-Specific T Cell and Viral Control in Chronic HBV Infection Using a Cultured ELISPOT Assay

Ex Vivo Detection and Characterization of Hepatitis B Virus-Specific CD8(+) T Cells in Patients Considered Immune Tolerant

Host Immunity Influences Disease Progression and Antiviral Efficacy in Humans Infected With Hepatitis B Virus

Innate and Adaptive Immune Responses in Chronic Hepatitis B Virus Infections: Towards Restoration of Immune Control of Viral Infection

Noncytolytic Control of Viral Infections by the Innate and Adaptive Immune Response

The Role of Quantitative Hepatitis B Surface Antigen Revisited

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.